OKYO Pharma Limited (NasdaqCM: OKYO)
Health Care · Biotechnology · GB
$1.54
+1.32% today · -36.6% 1Y
OKYO Pharma Limited (NasdaqCM: OKYO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $80.82M and employs 5 people.
Over the last twelve months the share price has lost 36.6%, trading between 1.34 and 3.20.
Tweenvest scores OKYO Pharma Limited across four factors: quality 26/100. Its strongest factor is quality.
OKYO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $80.82M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.24
- Dividend yield
- —
- Beta (5Y)
- 0.02
- 52-week high
- $3.20
- 52-week low
- $1.34
- Avg volume (3M)
- —
- Shares outstanding
- 52.48M
- Employees
- 5
- Next earnings
- —
About OKYO Pharma Limited
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
- ISIN
- GG00BMFG5F62
- Founded
- 2007
- Listed since
- May 17, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.